Company intelligence / Profile preview
Virogen Biotechnology
Pleasanton, California, United Statesvirogenbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
VG712 has demonstrated promising safety and efficacy in a completed Phase 1 trial for cutaneous T-cell lymphoma. The drug shows rapid, transient depletion of all T cell subtypes without triggering cytokine release syndrome or toxicity to other immune cells. It is more efficacious than standard agents like alemtuzumab or rATG at clearing T cells from blood, skin, and lymph nodes with minimal adverse effects. A pivotal Phase 2 trial is ongoing with plans to expand into additional indications including use as a lymphodepletion agent prior to adoptive cell therapies such as CAR-T.
- Therapeutic areas
- ImmunologyOncology
- Modalities
- Antibody toxin conjugate ("immunotoxin")Fusion protein therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Moffitt Cancer Center — strategic partnership focused on accelerating development of VG712 across oncology/immunotherapy applications.WuXi Biologics — contract manufacturing partner providing process validation and commercial-scale production services for VG712 using microbial fermentation platforms.
Beyond the preview
Go deeper on Virogen Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Virogen Biotechnology.